Heping Cai

Ms. Heping Cai


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZWZhen Wang
Zhen Wang
WZWanqun Zheng
Wanqun Zheng
ZCZhen Chen
Zhen Chen
SWShilun Wu
Shilun Wu
HCHaoxiao Chang
Haoxiao Chang
HCHeping Cai
Heping Cai
Background: Recent evidence increasingly suggests key roles for the tricarboxylic acid cycle and fatty acid metabolism in tumor progression and metastasis. Aconitase 2 (ACO2) is a component of the tricarboxylic acid cycle and represents a key cellular metabolic hub that promotes de novo fatty acid biosynthesis. However, there have been few reports on the role of ACO2 in tumorigenesis and cancer progression.Methods: Through the comprehensive use of datasets from The Cancer Genome Atlas, Genotype-Tissue Expression Project, cBioPortal, Human Protein Atlas, UALCAN, Gene Expression Profiling Interactive Analysis, DNA Methylation Interactive Visualization Database, and TIMER2, we adopted bioinformatics methods to uncover the potential carcinogenic roles of ACO2, including by analysing ACO2 expression and correlations between prognosis, genetic mutations, immune cell infiltration, DNA methylation, tumor mutational burden, and microsatellite instability in different tumors. Additionally, the expression level and tumor-promoting effect of ACO2 were verified in hepatocellular carcinoma (HCC) cells. To explore the underlying mechanisms of ACO2 in human cancer, ACO2-related gene enrichment analysis and lipid metabolomics were performed using LM3 cells with or without ACO2 knockdown.Results: The results indicated that ACO2 was highly expressed in most cancers, showing early diagnostic value in six tumor types, and was positively or negatively associated with prognosis in different tumors. Moreover, ACO2 expression was associated with immune cell infiltration, such as CD8+ T cells and tumor-associated neutrophils, in some cancers. For most cancer types, there was a significant association between immune checkpoint-associated genes and ACO2 expression. Compared with normal hepatocytes, ACO2 was upregulated in HCC cells, which promoted their proliferation and migration. Furthermore, to explore the underlying molecular mechanism, we performed KEGG pathway enrichment analysis of ACO2-associated genes and lipidomics using LM3 cells with or without ACO2 knockdown, which screened 19 significantly altered metabolites, including 17 with reduced levels and 2 with increased levels.Conclusion: Through pan-cancer analysis, we discovered for the first time and verified that ACO2 could be a useful diagnostic biomarker for cancer detection. Additionally, ACO2 could be used as an auxiliary prognostic marker or as a marker for immunotherapy in some tumor types.

24 September 2025 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
BYBiao Yu
Biao Yu
KMKangkang Mei
Kangkang Mei
DZDidi Zhan
Didi Zhan
QTQi Tang
Qi Tang
HCHeping Cai
Heping Cai
RZRuncong Zhang
Runcong Zhang
Background and Objectives Vancomycin (VCM) pharmacokinetic parameters vary widely between individuals. Existing models developed domestically and internationally may not apply universally because of differences in patient populations and testing methodologies. Therefore, the present study aimed to address the clinical challenge of optimizing individualized VCM dosing in pediatric patients at the study institution by developing a VCM population pharmacokinetic model and identifying key factors influencing VCM clearance, thereby providing a reference for safe and effective clinical dosing strategies. Methods Data regarding 124 effective VCM concentrations and 100 pediatric patients who received intravenous VCM were retrospectively collected. We used a non-linear mixed-effects model with forward inclusion and backward elimination to create the final VCM population pharmacokinetic model. The model was internally validated using bootstrapping, goodness of fit, and visual predictive check. The Monte Carlo method was used to simulate the range of trough concentrations in pediatric patients with renal insufficiency and normal function under different dosing regimens. Results A one-compartment model adequately described the pharmacokinetic behavior of VCM in vivo. The typical values of clearance and volume of distribution were 8.22 L/h and 113 L, respectively. Renal function and body weight were the most important factors affecting the clearance of VCM. The model was validated as stable and reliable. Conclusions The VCM population pharmacokinetic model established during this study can assist physicians with the development and optimization of dosing regimens for pediatric patients.

1 January 2026 in International Immunopharmacology
Verified
Journal Article
Closed access
XHXiao-Wei Hu
Xiao-Wei Hu
YWYu-Qing Wang
Yu-Qing Wang
XLXiang-Yu Li
Xiang-Yu Li
XSXiao-Yu Shen
Xiao-Yu Shen
RSRun-Run Shan
Run-Run Shan
QYQin Yang
Qin Yang

1 October 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
BYBiao Yu
Biao Yu
YWYing Wan
Ying Wan
WJWenbo Ji
Wenbo Ji
JMJuehui Mao
Juehui Mao
RZRuncong Zhang
Runcong Zhang
HCHeping Cai
Heping Cai
Purpose: Teicoplanin (TEC) is widely used for treating invasive infections caused by Gram-positive bacteria. Due to its high pharmacokinetic variability, several population pharmacokinetic (PPK) studies have been performed to identify factors contributing to the variability. This review aims to provide a comprehensive overview of published PPK studies and explore potential covariates. Patients and Methods: We systematically searched the PubMed, Web of Science, and Embase databases and compared study characteristics, model parameters, and covariate effects. Visual predictive distributions were used to compare different models. Forest plots and Monte Carlo simulations were used to assess the influence of covariates and probability of target attainment (PTA) against methicillin-resistant Staphylococcus aureus (MRSA). Results: A total of eight PPK studies involving preterm infants, neonates, infants, children, and adolescents were finally included. The median weight-normalized clearance (CL) in adolescents was 0.0116 L/h/kg, 14.7% and 16.0% lower than that in infants and children, respectively, and significantly approximately 22.7% lower than that in neonates. Key covariates impacting TEC clearance included body weight, postmenstrual age (PMA), renal function parameters, albumin levels, and continuous kidney replacement therapy (CKRT) status. Monte Carlo simulations indicated that current dosing regimens may be inadequate, particularly when treating MRSA with minimum inhibitory concentration (MIC) = 2 mg/L, as the PTA for AUC24/MIC≥ 400 often fell below 90%. Conclusion: TEC dosing in pediatric patients should be individualized, taking into account factors like age, weight, and renal function. Moreover, further population studies are essential to be conducted to clarify the dose-exposure-response relationship of TEC. PROSPERO Registration: CRD420251012884

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
BYBiao Yu
Biao Yu
YWYing Wan
Ying Wan
KMKangkang Mei
Kangkang Mei
DZDidi Zhan
Didi Zhan
QTQi Tang
Qi Tang
HCHeping Cai
Heping Cai
Purpose: The current study was designed to develop and validate a population pharmacokinetic (PPK) model of methotrexate (MTX) in pediatric patients with acute lymphoblastic leukemia (ALL). We aimed to develop a PPK model to evaluate the effects of potential covariates and explore dosing regimen. Patients and Methods: We retrospectively analyzed data from 214 pediatric patients with ALL who received high-dose methotrexate (HD-MTX) therapy, incorporating a total of 1672 plasma concentration measurements. Plasma samples were assayed using Enzyme-Multiplied Immunoassay Technique (EMIT). The PPK model was developed using a nonlinear mixed-effects model approach utilizing the NONMEM 7.4 software. Monte Carlo simulation was conducted to optimize the dosage regimen. Results: A two-compartment model with a 1-year age cutoff was found to adequately describe the PK disposition of MTX. The population typical values for clearance (CL) and volume of distribution (V) were 4.46 L/h and 15.9 L, respectively. Estimated glomerular filtration rate (eGFR) was identified as the most significant covariate, with body weight and blood urea nitrogen (BUN) also emerging as primary factors influencing CL. The model exhibited satisfactory predictive performance, with bootstrap analysis showing a 93.6% success rate. For external validation, the median prediction error (MPE) and median absolute prediction error (MAPE) were − 3.99% and 22.4%, respectively. Additionally, 46.36% of prediction errors fell within ± 20%, and 64.55% within ± 30%, confirming the model’s acceptable predictive performance. Monte Carlo simulations showed that optimized loading doses significantly improved steady-state MTX levels and reduced delayed elimination, especially in patients with renal impairment (eGFR < 100 mL/min/1.73m²). Conclusion: The PPK model established in this study can well predict the MTX exposure level in children with ALL, and it clearly identifies renal function status as a key basis for adjusting the loading dose. Combined with the results of Monte Carlo simulations, we propose that for patients with mild to moderate renal insufficiency, increasing the loading dose and prolonging the infusion time can improve the steady-state concentration compliance rate while reducing the risk of delayed excretion, providing a more targeted reference for clinical decision-making.